Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.83B | 1.72B | 1.24B | 1.14B | 1.04B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.83B | 1.72B | 1.24B | 1.14B | 1.04B |
| Cost of Revenue | 310.41M | 275.81M | 232.62M | 188.06M | 168.82M |
| Gross Profit | 1.52B | 1.45B | 1.00B | 955.39M | 868.60M |
| SG&A Expenses | 795.65M | 807.87M | 844.55M | 799.85M | 770.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.11B | 2.08B | 2.06B | 1.93B | 1.82B |
| Operating Income | -282.18M | -354.39M | -826.29M | -788.15M | -785.07M |
| Income Before Tax | -433.52M | -502.85M | -1.06B | -1.06B | -1.13B |
| Income Tax Expenses | 6.73M | 7.01M | 4.00M | 4.92M | 4.16M |
| Earnings from Continuing Operations | -440.24 | -509.87 | -1.06K | -1.06K | -1.13K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -440.24M | -509.87M | -1.06B | -1.06B | -1.13B |
| EBIT | -282.18M | -354.39M | -826.29M | -788.15M | -785.07M |
| EBITDA | -228.12M | -299.50M | -774.14M | -739.07M | -740.60M |
| EPS Basic | -3.53 | -4.12 | -8.62 | -8.70 | -9.30 |
| Normalized Basic EPS | -2.09 | -2.49 | -4.97 | -5.00 | -5.22 |
| EPS Diluted | -3.56 | -4.16 | -8.63 | -8.71 | -9.31 |
| Normalized Diluted EPS | -2.13 | -2.53 | -4.97 | -5.00 | -5.22 |
| Average Basic Shares Outstanding | 499.60M | 497.26M | 494.20M | 490.44M | 486.72M |
| Average Diluted Shares Outstanding | 505.72M | 503.37M | 494.20M | 490.44M | 486.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |